Aquinox Pharmaceuticals (NASDAQ:AQXP) has been given a $22.00 price target by equities researchers at Canaccord Genuity in a research note issued on Monday. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity’s price target would suggest a potential upside of 108.14% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. Needham & Company LLC reiterated a “buy” rating and issued a $25.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Cantor Fitzgerald reiterated a “buy” rating and issued a $28.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Zacks Investment Research cut Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. Finally, ValuEngine cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $22.50.

Shares of Aquinox Pharmaceuticals (NASDAQ AQXP) traded down $0.03 on Monday, hitting $10.57. The stock had a trading volume of 95,500 shares, compared to its average volume of 85,455. Aquinox Pharmaceuticals has a fifty-two week low of $10.20 and a fifty-two week high of $19.97.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Alps Advisors Inc. lifted its stake in Aquinox Pharmaceuticals by 4.7% during the second quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock worth $297,000 after purchasing an additional 939 shares during the last quarter. Northern Trust Corp lifted its stake in Aquinox Pharmaceuticals by 3.3% during the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock worth $1,171,000 after purchasing an additional 2,691 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Aquinox Pharmaceuticals by 16.5% during the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after purchasing an additional 3,299 shares during the last quarter. Alyeska Investment Group L.P. lifted its stake in Aquinox Pharmaceuticals by 1.8% during the third quarter. Alyeska Investment Group L.P. now owns 282,569 shares of the company’s stock worth $4,010,000 after purchasing an additional 5,046 shares during the last quarter. Finally, Archon Partners LLC lifted its stake in Aquinox Pharmaceuticals by 44.0% during the second quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock worth $253,000 after purchasing an additional 5,500 shares during the last quarter. Institutional investors and hedge funds own 96.25% of the company’s stock.

WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/11/aquinox-pharmaceuticals-aqxp-given-a-22-00-price-target-by-canaccord-genuity-analysts.html.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.